(Hypertension. 2000;35:501.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Effect of the Angiotensin II Type 1 Receptor Blocker Candesartan on Endothelial Function in Patients With Essential Hypertension
From the Department of Internal Medicine, University of Pisa, Pisa, Italy.
Correspondence to Dr Stefano Taddei, Dept of Internal Medicine, University of Pisa, Via Roma, 67 56100 Pisa, Italy. E-mail s.taddei{at}int.med.unipi.it
Abstract—Patients with essential hypertension are characterized by impaired basal and agonist-evoked nitric oxide release and increased endogenous endothelin (ET)-1–induced vasoconstriction. To assess whether candesartan, an angiotensin II type 1 receptor blocker, can improve endothelial function, we studied the changes in forearm blood flow (FBF) induced in 15 hypertensive patients and in 15 control subjects by the intrabrachial infusion of NG-monomethyl-L-arginine (L-NMMA), norepinephrine, the ET A/B receptor antagonist TAK 044, sodium nitroprusside, and acetylcholine. In hypertensive patients, the FBF study was repeated 2 and 12 months after the start of treatment with candesartan cilexetil (8 to 16 mg daily). Compared with controls (maximal FBF decrease, -46±11%), hypertensive patients showed a reduced (P<0.001) vasoconstrictor response to L-NMMA (maximal FBF decrease, -28±7%); the response to norepinephrine was only slightly impaired, and the response to sodium nitroprusside was similar to that of controls. Finally, TAK-044 caused greater vasodilation in hypertensive patients (maximal FBF increase, 77±9%) than in controls (maximal FBF increase, 17±10%). In hypertensive patients, candesartan cilexetil significantly enhanced vasoconstriction to L-NMMA after 2 and 12 months (maximal FBF decrease, 37±2% [P<0.05] and 42±2% [P<0.001], respectively). The responses to norepinephrine, acetylcholine, and sodium nitroprusside were not modified after 2 months. After 12 months, the responses to acetylcholine and sodium nitroprusside were significantly (P<0.05) enhanced at the highest rates. Vasodilation to TAK-044 was abolished after treatment with candesartan cilexetil; this effect is associated with a reduced plasma ET-1 concentration. This study demonstrated that the angiotensin II receptor blocker candesartan improves tonic nitric oxide release and reduces vasoconstriction to endogenous ET-1 in the forearm of hypertensive patients.
Key Words: endothelium • nitric oxide • endothelin • angiotensin antagonist • hypertension, essential
This article has been cited by other articles:
 |
|
 |
|
  M. Kosch, A. Levers, D. Lang, V. Bartels, K. H. Rahn, H. Pavenstadt, and M. Hausberg A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2280 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsukuda, M. Mogi, J.-M. Li, J. Iwanami, L.-J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi Amelioration of Cognitive Impairment in the Type-2 Diabetic Mouse by the Angiotensin II Type-1 Receptor Blocker Candesartan Hypertension, December 1, 2007; 50(6): 1099 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Schrage, J. H. Eisenach, and M. J. Joyner Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans J. Physiol., February 15, 2007; 579(1): 227 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Feletou and P. M. Vanhoutte Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture) Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H985 - H1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watanabe, J. Suzuki, H. Yamawaki, V. K. Sharma, S.-S. Sheu, and B. C. Berk Losartan Metabolite EXP3179 Activates Akt and Endothelial Nitric Oxide Synthase via Vascular Endothelial Growth Factor Receptor-2 in Endothelial Cells: Angiotensin II Type 1 Receptor-Independent Effects of EXP3179 Circulation, September 20, 2005; 112(12): 1798 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sanz-Rosa, M. P. Oubina, E. Cediel, N. de las Heras, O. Vegazo, J. Jimenez, V. Lahera, and V. Cachofeiro Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-{kappa}B/I{kappa}B system Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H111 - H115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mahmud and J. Feely Review: Arterial stiffness and the renin-angiotensin-aldosterone system Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 102 - 108. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Sim, C. Farquharson, and A. D Struthers Tonic levels of angiotensin II reduce tonic levels of vascular nitric oxide even in salt-replete man Journal of Renin-Angiotensin-Aldosterone System, June 1, 2004; 5(2): 84 - 88. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Delles, G. Michelson, J. Harazny, S. Oehmer, K. F. Hilgers, and R. E. Schmieder Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients Stroke, June 1, 2004; 35(6): 1289 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kadowaki and N. Kubota Protective Role of Imatinib in Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 801 - 803. [Full Text]
|
|
|
|
 |
|
 H. Thai, J. Wollmuth, S. Goldman, and M. Gaballa Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1171 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, J. Y. Ahn, S. H. Han, D. S. Kim, D. K. Jin, H. S. Kim, M.-S. Shin, T. H. Ahn, I. S. Choi, and E. K. Shin Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients J. Am. Coll. Cardiol., September 3, 2003; 42(5): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cediel, D. Sanz-Rosa, M. P. Oubina, N. de las Heras, F. R. G. Pacheco, O. Vegazo, J. Jimenez, V. Cachofeiro, and V. Lahera Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R674 - R681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zalba, G. S. Jose, M. U. Moreno, M. A. Fortuno, A. Fortuno, F. J. Beaumont, and J. Diez Oxidative Stress in Arterial Hypertension: Role of NAD(P)H Oxidase Hypertension, December 1, 2001; 38(6): 1395 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Rossi, S. Taddei, A. Virdis, L. Ghiadoni, G. Albertin, S. Favilla, I. Sudano, A. C. Pessina, and A. Salvetti Exclusion of the ACE D/I Gene Polymorphism as a Determinant of Endothelial Dysfunction Hypertension, February 1, 2001; 37(2): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. A. van Ampting, M. L. Hijmering, J. J. Beutler, R. E. van Etten, H. A. Koomans, T. J. Rabelink, and E. S. G. Stroes Vascular Effects of ACE Inhibition Independent of the Renin-Angiotensin System in Hypertensive Renovascular Disease : A Randomized, Double-Blind, Crossover Trial Hypertension, January 1, 2001; 37(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|